

Applicants : BERMUDEZ, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 4

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 - 43 (Canceled)

44. (Currently Amended) An attenuated *Salmonella* sp. which expresses an F' pilus and contains ~~produces~~ a filamentous bacteriophage, whereby said *Salmonella* sp. ~~*Salmonella*~~ ~~strain~~ is a *msbB*⁻ mutant and said bacteriophage expresses a proteinaceous molecule under the control of a eukaryotic promotor ~~non-pyrogenic and tumor-targeting.~~

45. (Canceled)

46. (Currently Amended) The *Salmonella* sp. of claim 44 ~~45~~, wherein the *Salmonella* sp. ~~*enteritidis*~~ is *Salmonella typhimurium*.

47. (Currently Amended) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. is further attenuated by ~~a mutation selected from the group consisting of a lipid mutation, a pur⁻ mutation, and a combination thereof.~~

48. (Canceled)

49. (Currently Amended) The *Salmonella* sp. of claim 46, wherein the *Salmonella typhimurium* is ~~derived from the strain~~ selected from the group consisting of YS72 (ATCC Accession

Applicants : BERMUDEZ, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 5

No. 55680), YS1456 (ATCC Accession No. 202164), and YS1646 (ATCC Accession No. 202165).

50. (Canceled)

51. (Canceled)

52. (Currently Amended) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. delivers at least ~~1.7~~ 2.7×10^9 p.f.u. (plaque forming unit) of bacteriophage/gram of tumor.

53. (Currently Amended) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. delivers about ~~5.9~~ 17×10^9 p.f.u. (plaque forming unit) of bacteriophage/gram of tumor.

54. (Canceled)

55. (Currently Amended) The *Salmonella* sp. of claim ~~54~~ 44, wherein the proteinaceous molecule is selected from the group consisting of green fluorescent protein (GFP), IL-2/pIII fusion protein, and listeriolysin O (LLO) 91-99.

56. (Canceled)

57. (Currently Amended) The *Salmonella* sp. of claim ~~56~~ 44, wherein the eukaryotic promoter is a cytomegalovirus (CMV) promoter.

58. (Original) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. is lac⁺ and kanamycin-resistant.

Applicants : BERMUDEZ, et al.
U.S. Serial No.: 10/790,586
Filed : March 1, 2004
Page : 6

59. (Canceled)

60. (Original) A composition comprising the *Salmonella sp.* of claim 44 and a pharmaceutically-acceptable carrier.

61. (Currently Amended) A method of delivering a bacteriophage to a solid tumor, comprising the intravenous administration of an attenuated ~~tumor-targeting~~ *Salmonella sp.* which expresses an F' pilus and contains ~~produces~~ a filamentous bacteriophage, whereby said *Salmonella sp.* ~~*Salmonella*~~ strain is a *msbB* mutant and said bacteriophage expresses a proteinaceous molecule under the control of a eukaryotic promoter ~~non-pyrogenic and tumor targeting~~.

62. (Currently Amended) A kit comprising an attenuated *Salmonella sp.* which expresses an F' pilus and contains ~~produces~~ a filamentous bacteriophage, whereby said *Salmonella sp.* ~~*Salmonella*~~ strain is a *msbB* mutant and said bacteriophage expresses a proteinaceous molecule under the control of a eukaryotic promoter ~~non-pyrogenic and tumor targeting~~.